Previous Article | Next Article 
Journal of Clinical Microbiology, July 1999, p. 2297-2305, Vol. 37, No. 7
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Evaluation of Mycology Laboratory Proficiency
Testing
Andrew A.
Reilly,1,2,*
Ira F.
Salkin,1,2
Michael R.
McGinnis,3
Sally
Gromadzki,1
Lester
Pasarell,3
Maggi
Kemna,1
Nancy
Higgins,1 and
Max
Salfinger1,4
Wadsworth Center, New York State Department
of Health,1 and Department of Medicine,
Albany Medical College,4 Albany, and
School of Public Health, The University at Albany,
Rensselaer,2 New York, and Center
for Tropical Diseases, Department of Pathology, University of Texas
Medical Branch, Galveston, Texas3
Received 16 December 1998/Returned for modification 8 February
1999/Accepted 19 April 1999
 |
ABSTRACT |
Changes over the last decade in overt proficiency testing (OPT)
regulations have been ostensibly directed at improving laboratory performance on patient samples. However, the overt (unblinded) format
of the tests and regulatory penalties associated with incorrect values
allow and encourage laboratorians to take extra precautions with OPT
analytes. As a result OPT may measure optimal laboratory performance
instead of the intended target of typical performance attained during
routine patient testing. This study addresses this issue by
evaluating medical mycology OPT and comparing its fungal specimen
identification error rates to those obtained in a covert (blinded)
proficiency testing (CPT) program. Identifications from 188 laboratories participating in the New York State mycology OPT from 1982 to 1994 were compared with the identifications of the same fungi
recovered from patient specimens in 1989 and 1994 as part of the
routine procedures of 88 of these laboratories. The consistency in the
identification of OPT specimens was sufficient to make accurate
predictions of OPT error rates. However, while the error rates in OPT
and CPT were similar for Candida albicans, significantly higher error rates were found in CPT for
Candida tropicalis, Candida glabrata, and other
common pathogenic fungi. These differences may, in part, be due to
OPT's use of ideal organism representatives cultured under
optimum growth conditions. This difference, as well as the
organism-dependent error rate differences, reflects the limitations of
OPT as a means of assessing the quality of routine laboratory
performance in medical mycology.
 |
INTRODUCTION |
The New York State Public Health Law
requires all clinical laboratories and blood banks conducting tests on
specimens collected within New York State to hold a state clinical
laboratory permit, unless the tests are conducted as an adjunct to a
physician's medical practice (physician office laboratory). In
response to a 1964 legislative mandate, the New York State
Department of Health initiated an overt proficiency testing (OPT)
program as one method of monitoring the overall quality of
testing performed by state permit-holding clinical facilities. The
program, as of 1998, has grown to include almost 1,000 clinical
facilities, both within New York State and in over 30 other states. Of
these, 188 hold permits in medical mycology to isolate and identify
either yeast-like potential pathogens only (limited permit) or all
fungi and aerobic actinomycetes (general permit) which may be recovered
from clinical specimens.
After learning of widely publicized problems found in the screening of
Papanicolaou smears in cytopathology laboratories, Congress enacted the
Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). The
statute and enabling regulations initially required, in part, that all
sites conducting laboratory tests on human specimens must participate
in federally approved OPT programs. While the regulatory burden has
been lightened over the years, current CLIA '88 regulations require
approximately 40% of all federally registered test facilities to
participate in one of 20 OPT programs approved by the Health Care
Financing Administration. Proficiency testing has gained wide
acceptance as a regulatory tool; the maintenance of clinical laboratory
operating licenses at state and federal levels are chiefly dependent
upon successful OPT performance.
There have been few investigations of the ability of OPT
to evaluate a laboratory's routine testing capability.
Previous studies primarily described the effects of the number
and type of test specimens, laboratory personnel qualifications, and
test methodology, etc., on proficiency test results (7, 15, 17,
18, 21, 30). This investigation was undertaken to compare the
identification of fungi reported by laboratories which participated in
the New York State mycology OPT to those reported by these facilities for the same fungi isolated from routine clinical specimens that had
been obtained during unanticipated surveyor collections (covert proficiency testing [CPT]).
 |
MATERIALS AND METHODS |
Laboratories studied.
The OPT portion of the study includes
all 188 laboratories holding mycology permits whose test-specific
results are stored in the department's electronic records for tests
between September 1989 and May 1994. In order to enhance the assessment
of long-term trends, these data were augmented with results of
semiannual OPT events conducted between January 1982 and September
1989, even though only aggregate, rather than laboratory-specific,
electronic records were available from these earlier tests (Table
1).
The CPT portion of the study includes isolates from routine patient
specimens and laboratory identifications of them obtained by state
surveyors during regular semiannual inspections. The isolates were
analyzed by both the New York State Laboratories for Mycology and a
reference laboratory. CPT was a double-blinded investigation, in that
laboratories did not know which fungal isolates would be selected for
confirmatory testing during the on-site inspections. Additionally,
during reanalysis both confirmatory laboratories were unaware of the
isolates' sources and original identifications.
OPT.
From 1982 to 1991, 10 test specimens were sent twice
each year (total of 20 specimens) to each participating laboratory. In the fall of 1991, the content and number of test events were modified to five test specimens shipped four times each year (20 specimens). To
comply with CLIA '88 requirements, the frequency of test events and
number of test specimens were altered in the fall of 1993 to five test
specimens sent three times each year (15 specimens; Table 1).
Prior to OPT, a minimum of three strains of each of the proposed five
specimens were obtained from the Laboratories for Mycology
culture
collection or recent clinical specimens. The morphological
features of
each mold were evaluated. Physiological characteristics,
e.g.,
temperature optimum and growth on cycloheximide-containing
media,
etc., were examined through the use of appropriate supplemental
tests
(
23). The morphologies of all yeasts were studied with
yeast
grown on cornmeal agar plus Tween 80 in 100-mm-diameter
petri dishes
inoculated by the Dalmau or streak-cut methods. Carbohydrate
assimilation characteristics were determined by using the API
20C
system (Biomerieux-Vitek, Hazelwood, Mo.) and other commercial
yeast
identification kits. Supplemental physiological characteristics,
e.g.,
nitrate assimilation, urease activity, and temperature optimum,
etc., were studied with appropriate test media (
23). Based
upon
the results of these tests on each strain, the strains that
demonstrated
the best morphological and physiologic
characteristics were selected
for use in the test
event.
CPT.
The 88 laboratories in the CPT portion of the study
were a subset of the OPT participants selected on the basis of sample availability and the surveyor's inspection schedules.
Specimens were obtained from 66 laboratories in 1988 and 1989 and 57 laboratories in 1993 and 1994. Isolate availability led
to 22 of these
57 not being included among the 1988 and 1989 inspections
(Table
1).
The collected isolates (nominally three yeasts and
two molds or aerobic
actinomycetes) were recently recovered from
clinical specimens and
identified by the laboratory as part of
its routine workload, i.e.,
CPT.
Isolates were immediately shipped to the Laboratories for Mycology by
the surveyors where they were accessioned, subcultured,
and
reidentified by standard methods (
23). To independently
validate the identifications done by the permit-holding laboratories
and Wadsworth Center's Laboratories of Mycology, additional
subcultures
of all isolates were prepared and submitted to the Mycology
Reference
Laboratory at the University of Texas Medical Branch,
Galveston.
All CPT results refer only to 452 of 466 viable specimens
(97%)
on which both confirmatory laboratories agreed on the
identification.
Statistical methods.
The sparseness of available OPT and CPT
data necessitated pooling results from all participating laboratories.
These aggregated data were examined for the possibility of combining
test and collection events and again pooled. Because many of the fungi
were infrequently seen in either a clinical setting or OPT, the doubly
pooled data were coalesced further into four groups of related molds (I
to IV) and two groups of yeasts (V and VI). However, the test results for individual organisms were retained for analysis whenever sufficient data had been collected to make statistical comparisons, i.e., for
Aspergillus fumigatus, Trichophyton tonsurans,
Candida albicans, Candida parapsilosis,
Candida tropicalis, Candida glabrata, and Cryptococcus neoformans.
Error rates were estimated by maximum likelihood (
11) with
truncated Poisson distributions (
22), which account for
laboratories'
multiple encounters with the same organism. The
resulting error
rate parameter estimates, which vary directly with the
ease with
which an organism or group could be identified, were tested
for
statistically significant OPT and CPT differences by using a
likelihood
ratio goodness of fit test (
4).
The time trends from the more voluminous historical OPT data were
assessed by using logistic regression maximum likelihood
estimation of
the changes in error rates with respect to time
(
8). The
significance of the rate of change (slope) was assessed
with a
chi-square test. All programming, which is available upon
request, was
done in APL (
29).
 |
RESULTS |
Over 105 laboratories participated in each of the semiannual OPT
events between 1982 and 1989. Laboratory participation during the 1989 to 1994 period was stable, with less than 7% turnover in the three or
four events per year (data not shown). However, due to the merger of
the separate OPT programs operated by the New York City and New York
State Departments of Health, 28 general- and 54 limited-permit
laboratories joined the program in 1994.
The laboratories participating in the post-1988 OPT and CPT portions of
the study were distributed throughout the state in proportion to the
size of the populations of each region, except for New York City (Table
2 and Fig.
1). Approximately half (44 to 63%) of
the laboratories in each region held general permits. However, since
facilities in New York City were not totally integrated into the state
OPT program until 1995, there were significantly fewer (P < 0.0001) New York City laboratories that participated in the CPT.
CPT samples were collected from fewer non-hospital-based laboratories,
16 of 88 (18%), than OPT samples, 49 of 188 (26%), but this
difference was not statistically significant (P > 0.05).
The error rates for identifying mold and yeast specimens (Table
3) in OPT events over the combined 1982 to 1994 period are shown in Fig. 2 to
5.
Although the identification errors varied considerably among events,
logistic regression with respect to time revealed significant
longitudinal decreases. This effect was pronounced in the error rates
found in the identifications of selected mold and yeast test specimens
(Fig. 2 and 4). For example, while more than 50% of the participating
laboratories could not identify Cunninghamella spp. and
about 30% misidentified Cladophialophora carrionii (syn.
Cladosporium carrionii) in 1982, less than 5% of the
laboratories holding general permits erroneously identified either of
these two molds in 1994. Similarly, 25% or more of the permit-holding
laboratories did not appropriately identify Candida rugosa
and Candida krusei when first seen as proficiency test
specimens in the early 1980s. Less than 2% of the laboratories
misidentified these two yeast-like potential pathogens in OPT events in
1993 and 1994, respectively.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
OPT error rates observed in 1982 to 1994 for defined
mold groups (Table 3). Dashed lines, associated logistic regression
curves.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
OPT error rates for the five individual molds showing
the greatest decreases between 1982 and 1994. Symbols indicate the
observed percentages of errors committed at each event. Dashed lines,
associated logistic regression curves. All decreases were statistically
significant (P < 0.002).
|
|

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 4.
OPT error rates observed in 1982 to 1994 for defined
yeast groups (Table 3). Dashed lines, associated logistic regression
curves.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
OPT error rates for the five individual yeasts showing
the greatest decreases between 1982 and 1994. Symbols indicate the
observed percentages of errors committed at each event. Dashed lines,
associated logistic regression curves. All decreases were statistically
significant (P < 0.007).
|
|
Error rates estimates for the OPT and CPT data after September 1989 were derived from the number of times laboratories were tested with a
given organism. For example, Table 4
shows that 125 of the 188 permit-holding laboratories were mailed
isolates of Hansenula anomala at least once and that of the
52 laboratories that received the organism in three events, six
misidentified it once. The maximum likelihood truncated Poisson error
rate estimate is therefore 7.5%. Multiple recoveries of the same
organism, instead of multiple test events, in the CPT portion of this
study led to similar data for which the same estimation techniques were employed. Goodness of fit testing for each organism (not shown, except
in Table 4) failed to reject the truncated Poisson distribution as an
adequate model for the errors.
Figures 2 to 5 display initially rapid decreases in error rates that
generally tended to stabilize after 1988. A further assessment of
stability was achieved by utilizing the 1988 to 1994 OPT results to
predict the expected number of errors in post-1994 OPT events, before
the results were observed. The predicted and observed numbers of errors
are shown in Table 5 for representative
1995 and 1998 events. In the 1995 prediction the organisms listed in
Table 4 were used as the test samples. The P values of 0.93 for 1995 and 0.72 for 1998 indicate that the predictions cannot be
differentiated statistically from the observed results.
Thirteen organism-specific and grouped error rates estimated from
CPT samples collected in 1988 and 1989 were compared to those collected
in 1993 and 1994. No significant differences were detected between the
two time periods (Fig. 6).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 6.
Grouped and organism-specific comparison of CPT error
rates from 1988 to 1989 and 1993 to 1994 (Table 3). No errors were
observed in 1990 data for some groups (a). C. albicans had
only one error in 81 (1%) specimens from 1988 to 1989 but seven errors
in 77 (9%) specimens from 1994 to 1995 (P = 0.02) (b).
However, the figure displays 13 simultaneous comparisons so an
appropriate significance level is calculated by the following equation:
0.05/13 = 0.003. No errors were observed in data for some groups
(c).
|
|
Error rates in the identification of the majority of those individual
fungi for which sufficient data were collected for comparative analysis
were found to be statistically significantly greater in CPT than in OPT
(Fig. 7). While none of the participating
laboratories misidentified A. fumigatus in OPT specimens,
greater than 25% (P < 0.002) of the isolates of this
clinically significant mold were not correctly identified when
recovered from routine clinical specimens (CPT). Similarly, almost all
laboratories appropriately identified C. parapsilosis,
C. tropicalis, and C. glabrata in OPT events, but
about 15% (P < 0.005, P < 0.004, and
P < 0.005, respectively) of these yeasts were
misidentified when isolated as part of routine workloads. The
miscellaneous yeasts placed into group V were also significantly more
difficult to identify in CPT than as part of an OPT event (P < 0.008).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 7.
Grouped and organism-specific comparison of OPT and
combined CPT error rates from 1988 to 1994 (Table 3). For some groups
no errors were observed in OPT (a), in CPT (b), or in all data (c).
|
|
In contrast, there were no differences in the error rates found
in OPT and CPT in the identification of C. albicans
(11 versus 10%) and T. tonsurans (10 versus
12%). While there were differences from CPT in the capability of
participating laboratories to identify members of groups I to IV (13 to
25 CPT isolates) and group VI (three CPT isolates) when presented in
OPT events, small sample sizes prevented these differences from
becoming statistically significant.
 |
DISCUSSION |
The inferences drawn from this observational study are influenced
by its design, which did not randomly select laboratories and compare
their matched OPT and CPT performance through time. There is therefore
a possibility that differential selection biases and participant
turnover may have influenced the results. While the 188 OPT
participants are a census, the 88 CPT participants were haphazardly
selected, except that New York City laboratories were underrepresented.
This would be more troubling if there was not a high correlation of
laboratory location with regional population size to suggest that urban
laboratories continue to be represented in the CPT in other regions of
the state. The failure to find differences between the two time periods
in which CPT samples were collected is an indicator that the inclusion
of 22 new laboratories among the 1993 and 1994 CPT participants did not
introduce biases into the estimated error rates. Similarly, the low
number of participating laboratory changes in the OPT data suggests
that this contribution to bias was likely to be small. Finally, the
maximal OPT turnover was due to the introduction of new laboratories in
the last two events, and these have the smallest influence on the error
rate estimates, which are largely controlled by laboratories with
multiple-event organism-specific errors.
Permit holders must identify 80% of test specimens in two of three
consecutive OPT test events in order to qualify for and maintain their
permits. In contrast, for the purposes of this study, species-specific
identification errors were used to compare laboratory performances in
OPT and CPT. Ideally, precise species-specific error rates would be
estimated from a large data pool collected under both testing modes
from each laboratory on a single date. The effect of pooling the
data, required by the small numbers of samples, can be examined by
noting that of the 125 laboratories who participated in at least five
OPT events from 1988 to 1994, 79 (63%) had less than 10%
misidentifications, 39 (31%) misidentified 10 to 15%, and 7 (6%) had more than 15% misidentifications. Compared to a 10%
misidentification rate for the majority of facilities four of the seven
with more than 15% errors displayed significantly higher errors
(P < 0.05). Nevertheless, the distribution of errors displayed by all the laboratories is a continuum starting from a
minimum of 1.3% and ending at the maximum of 22.4% (data not shown).
Since all laboratories were pooled, the degree of the observed
differences therefore depends on the inclusion of a few laboratories
with noticeably poor performance.
Although it is possible that grouping could obscure differential
performance with a particular organism, segregating out such candidates
in these data will not identify additional significant differences due
to the small sample sizes. Coalescing the data into six groups, in
addition to selected individual organisms, has resulted in detecting
differences between CPT and OPT performances only for group V,
miscellaneous yeast. In group V the OPT organism most difficult to
identify was Geotrichum candidum, with 38 of 131 (29%) samples misidentified. No confirmed identified isolates of this
organism were recovered in CPT. The corresponding group V CPT error
estimates are therefore presumably smaller than if G. candidum had been recovered. Grouping, by retaining a
difficult organism in only the OPT part of the comparison, has
therefore introduced a bias diminishing the estimated OPT-CPT differences.
The significantly decreasing error rates in identification of mold and
yeast test specimens found in the longitudinal OPT portion of the study
provide evidence that OPT is useful as an educational tool and thereby
successfully fulfills one of its goals (25). Coupling this
with the low laboratory turnover suggests that the presentation
of clinically significant fungi in OPT events is correlated with
improved OPT performance over time. Many of the OPT events were
composed of organisms rarely seen in patient samples (Table 3),
encouraging participants to enhance their identification capabilities.
This contributed to more than 95% of the laboratories correctly
identifying mold and/or yeast specimens in each of the later OPT
events. Error rates for many of the test organisms employed in OPT were
found to be so consistent over the later portion of the study period,
1988 to 1994, that 1995 to 1998 event results could be predicted prior
to the shipment of test specimens. A control group of laboratories
sampled over the same time period but not subjected to OPT is needed to
confirm that the improvement was due solely to the state OPT. Although such control laboratories do not exist, participants indicated that
greater efforts were expended to correctly identify isolates, particularly after failures in the early 1980s.
Improved OPT performance may or may not indicate that the
diagnostic capabilities of participating laboratories simultaneously improve. The CPT study examined patient specimens from
permitted laboratories during two periods of recent performance and
found no significant changes in error rates. The differences between the OPT and CPT performances, discovered by putting the
analysis on an organism- or group-specific basis, correspond to the
relative difficulty of the identification. Commonly seen and easily
identified fungi such as C. albicans and T. tonsurans were misidentified about 10% of the time under both
protocols. The differential misidentification rates of A. fumigatus, C. parapsilosis, C. tropicalis, C. glabrata, and group V organisms are
disquieting. These differences may, in part, be due to OPT's use of
ideal representatives monocultured under optimum growth conditions.
Alternatively, laboratories have the motivation and opportunity to
expend greater efforts examining OPT isolates. For example, the 25%
higher misidentification rate for CPT isolates of A. fumigatus could be due to some laboratories' omitting parts of
the standard techniques used in the identification of this organism
when it is recovered from patient specimens.
There are several other ways that laboratories can favorably affect OPT
performance. For administration reasons schedules of OPT events are
announced at the beginning of each year. This information permits
participants to optimize their performance by coincidentally
scheduling reagent renewals and maintenance activities.
Additionally, there is sufficient volume in some test categories' OPT
samples for laboratories to perform multiple tests and report either
the best result or eliminate outliers and report an average of the
remainder. Finally, the most proficient medical mycology staff may be
specifically assigned to process the OPT samples and may spend extra
time and care in executing each analysis.
This intensive study of the value of OPT in clinical mycology relies on
detailed comparisons to error rates found in blind covert retrotesting,
i.e., to laboratory performances achieved on actual patient samples.
Previous reports on mycology OPT have described the fungi used as test
samples and the relationship of the volume of samples processed by
laboratories with their OPT performances (3, 10, 12, 13,
31). Published analyses of OPTs in mycobacteriology have
discussed the effects of the types of identification methods on the
results reported by the participating facilities, as well as described
test results over time (33). Investigations in other areas
of microbiology (14, 32) have dealt solely with the
evaluation of OPT test specimens, internal laboratory quality control
monitoring (2), or, as here, comparisons of OPT and blinded
specimens (5, 6, 24). Richardson et al. (24)
compared OPT results with routine work on patient specimens and
found that laboratories performing poorly on OPT lacked effective
quality control, used nonstandard methods, and failed to follow
in-house procedure manuals during analyses.
The selection of the current retrospective design was partially
motivated by the infeasibility of splitting fungal samples. However, Black and Dorse (5, 6) report on a
bacteriology study that used a simulated blind split sample
submission design. This design allowed the examination of performance
at all stages of normal specimen handling. Their results revealed that
some laboratories were unable to isolate organisms from the test
specimens confirmed positive. Additionally, they found correct
identifications of mucoid Escherichia coli decreased from
94% under OPT to 47% under CPT, as well as large decreases for
Yersinia enterocolitica (45%) and streptococcal
Lancefield group C (13%). Significant variation was also
found depending on whether the isolate was from urine, pus, or
feces. Additionally, in contrast to the results of this investigation,
the most commonly encountered organisms were among the worst
handled. These authors suggested that a laboratory's OPT
ability to identify (lyophylized) bacteria has little to do with its
performance on normal patient specimens.
Studies of OPTs in quantitative clinical areas, e.g., clinical
chemistry, diagnostic immunology, and hematology, etc., have concentrated on its use in evaluating interlaboratory variations associated with specific diagnostic techniques, establishing
grading criteria and reviewing personnel qualifications (1, 9,
18-20, 30). Hansen et al. (16) found greater than
50% decreases in correct analyses under CPT for barbiturates,
amphetamines, cocaine, codeine, and morphine. The authors speculated
that the 13 laboratories under study used a higher minimum reporting
level under CPT than under OPT. Inferences about drug testing
sensitivity obtained via OPT were therefore artificially inflated.
Sargent et al. (26) submitted 53 blinded specimens with
known blood lead concentrations to 18 laboratories. The samples had
concentrations more than 30% higher or lower than the Centers for
Disease Control and Prevention threshold of 10 µg/dl. With respect to
this threshold they estimated the correct classification rate (95%
confidence interval) to be in the range of 79 to 95%. OPT of about
100 laboratories with similar samples in the New York State Blood
Lead Proficiency Testing Program typically leads to more than 97% of
samples being correctly classified. In contrast, Schalla et al.
(27) found no difference between OPT and CPT in examining
the results of split samples sent to 262 participants testing for HIV antibodies.
The results of this and previous studies point to limitations on the
effectiveness of evaluating a laboratory's capability in medical
mycology under the OPT paradigm. The scheme mandated by CLIA '88
introduces further limitations. Fifteen specimens, presuming they were
all of a single species whose nominal error rate is 0, are sufficient
to identify only laboratories with greater than a 25% error rate
(at P = 0.05). However, test events are actually composed of a mixture of specimens of differing difficulties (Table 3), where the average nominal error rate is closer to 10% than
to 0. In this case 15 specimens, three events with nominal 10% rates,
are sufficient to identify only laboratories with greater than a 40%
error rate. Various adjustments to the scoring scheme further inflate
the error rate at which poor performers are identified. For example,
the OPT error rates found for Torulopsis candida, Blastoschizomyces capitatus, G. candidum, and
Candida lipolytica exceed 20%, but all laboratories
received passing scores under the rule requiring specimens with less
than 80% correct responses to be declared invalid.
We have considered in detail the open aspect of the CLIA '88 testing
scheme by comparing OPT species-specific results to double-blind covert
testing. For easily identified species, such as C. albicans, blinding the testing appears to make little difference. For
"difficult" species, such as A. fumigatus, whose nominal
error rate in OPT is close to 0, the open testing protocol fails
to identify laboratories whose usual error rate in the identification
of patient specimens exceeds 65%. These results, as well as the cited
concordant literature, clearly indicate the need for improving
proficiency testing schemes for some analytes.
OPT is only one of the tools used to maintain and improve the quality
of clinical laboratory services. In addition to laboratories' routine
internal quality control practices, they are regularly inspected
to check adherence to testing protocols, validation procedures,
and schedules for the maintenance and calibration of instrumentation.
Additionally, regulators provide consultation services to
laboratories actively seeking to improve the quality of their tests,
changing testing procedures, or failing OPT. Nevertheless, open
testing's primary importance derives from the CLIA '88 specification that the issuance and maintenance of state and federal licenses to
conduct clinical testing depend upon laboratories meeting the specified
OPT passing criteria. The CPT portion of this study suggests that
improvements to OPT could be achieved by supplementing normal open
testing with a sentinel system of blind testing with difficult
specimens. The obstacles and extra costs associated with submissions
and retrospective reanalyses are not insurmountable. One solution is to
administer CPTs to sequential participant subsets preferentially
constructed from laboratories with marginal performances. Even if
only a portion of the participants are to be tested, simply announcing the implementation of such a sentinel system is likely to
favorably impact performances on routine patient specimens at all laboratories.
The data presented suggest that (i) additional studies should be
conducted to enhance efficient statistical comparisons of fungal
identification error rates between OPT and CPT, (ii) OPT is not
an effective mechanism for evaluating the ability of clinical mycology
laboratories to identify all medically important fungi, and (iii) CPT,
despite its high costs and administrative problems, should be used on a
selective basis to augment OPT to obtain clearer perspectives of the
performance of clinical mycology laboratories (25, 28).
 |
ACKNOWLEDGMENTS |
This project was supported under a cooperative agreement from the
Centers for Disease Control and Prevention through the Association of
Schools of Public Health.
Special thanks go to Vishnu Chaturvedi, current director of the New
York State Laboratories for Mycology and the Mycology Proficiency
Testing Program, for supporting and reviewing the manuscript.
Additional thanks go to John Qualia and Teresa Wilson for assisting
with database management and computer program development.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Wadsworth
Center, Rm. C543, New York State Department of Health, P.O. Box 509, Albany, NY 12201-0509. Phone: (518) 473-3493. Fax: (518) 474-2769. E-mail: Andrew.Reilly{at}Wadsworth.Org.
 |
REFERENCES |
| 1.
|
Bakken, L. L.,
K. L. Case,
S. M. Callister,
N. J. Bourdeau, and R. F. Schell.
1992.
Performance of laboratories participating in a proficiency testing program for Lyme disease serology.
JAMA
268:891-895[Abstract/Free Full Text].
|
| 2.
|
Bartlett, R. C.,
M. Mazens-Sullivan,
J. Z. Tetreault,
S. Lobel, and J. Nivard.
1994.
Evolving approaches to management of quality in clinical microbiology.
Clin. Microbiol. Rev.
7:55-88[Abstract/Free Full Text].
|
| 3.
|
Bartola, J.
1988.
The importance of an effective proficiency testing program to the regulation of clinical laboratories. The view from one state.
Arch. Pathol. Lab. Med.
112:368-370[Medline].
|
| 4.
|
Bishop, Y. M. M.,
S. E. Fienberg, and P. W. Holland.
1975.
Discrete multivariate analysis: theory and practice, p. 123-155.
MIT Press, Cambridge, Mass.
|
| 5.
|
Black, W. A., and S. E. Dorse.
1976.
A regional quality control program in microbiology. I. Administrative aspects.
Am. J. Clin. Pathol.
66:401-406[Medline].
|
| 6.
|
Black, W. A., and S. E. Dorse.
1976.
A regional quality control program in microbiology. II. Advantages of simulated clinical specimens.
Am. J. Clin. Pathol.
66:407-415[Medline].
|
| 7.
|
Boone, D. J.,
H. J. Hansen,
T. L. Hearn,
D. S. Lewis, and D. Dudley.
1982.
Laboratory evaluation and assistance efforts: mailed, on-site and blind proficiency testing surveys conducted by the Centers for Disease Control.
Am. J. Public Health
72:1364-1368[Abstract/Free Full Text].
|
| 8.
|
Cox, D. R.
1970.
Analysis of binary data, p. 87-94.
Methuen & Co., Ltd., London, England.
|
| 9.
|
Dayian, G.,
D. L. Morse,
G. D. Schryver,
R. W. Stevens,
G. S. Birkhead,
D. J. White, and K. E. Hechemy.
1994.
Implementation of a proficiency testing program for Lyme disease in New York State.
Arch. Pathol. Lab. Med.
118:501-505[Medline].
|
| 10.
|
Dolan, C. T.
1974.
A summary of the 1972 mycology proficiency testing survey of the College of American Pathologists.
Am. J. Clin. Pathol.
61:990-993[Medline].
|
| 11.
|
Edwards, A. W. F.
1992.
Likelihood: an account of the statistical concept of likelihood and its application to scientific inference, rev. ed.
Johns Hopkins University Press, Baltimore, Md.
|
| 12.
|
Fuchs, P. C., and C. T. Dolan.
1981.
Summary and analysis of the mycology proficiency testing survey results of the College of American Pathologists.
Am. J. Clin. Pathol.
76:538-543[Medline].
|
| 13.
|
Griffin, C. W., III,
M. A. Mehaffey,
E. C. Cook,
S. O. Blumer, and P. A. Podeszwik.
1986.
Relationship between performance in three of the Centers for Disease Control microbiology proficiency testing programs and the number of actual patient specimens tested by participating laboratories.
J. Clin. Microbiol.
23:246-250[Abstract/Free Full Text].
|
| 14.
|
Griffin, C. W., III.,
E. C. Cook, and M. A. Mehaffey.
1986.
Centers for Disease Control performance evaluation program in bacteriology: 1980 to 1985 review.
J. Clin. Microbiol.
24:1004-1012[Abstract/Free Full Text].
|
| 15.
|
Hamlin, W.
1992.
Proficiency testing as a regulatory device: a CAP perspective.
Clin. Chem.
38:1234-1236[Abstract/Free Full Text].
|
| 16.
|
Hansen, H. J.,
S. P. Caudill, and D. J. Boone.
1985.
Crisis in drug testing. Results of CDC blind study.
JAMA
253:2382-2387[Abstract/Free Full Text].
|
| 17.
|
Howanitz, P. J.
1988.
Use of proficiency test performance to determine clinical laboratory director qualifications.
Arch. Pathol. Lab. Med.
112:349-353[Medline].
|
| 18.
|
Hurst, J.,
K. Nickel, and L. H. Hilborne.
1998.
Are physicians' office laboratory results of comparable quality to those produced in other laboratory settings?
JAMA
279:468-471[Abstract/Free Full Text].
|
| 19.
|
Jenny, R. W., and K. Y. Jackson.
1992.
Evaluation of the rigor and appropriateness of CLIA '88 toxicology proficiency testing standards.
Clin. Chem.
38:496-500[Abstract/Free Full Text].
|
| 20.
|
Jenny, R. W., and K. Y. Jackson.
1993.
Proficiency test performance as a predictor of accuracy of routine patient testing for theophylline.
Clin. Chem.
39:76-81[Abstract].
|
| 21.
|
Luntz, M. E.,
B. M. Castleberry, and K. James.
1992.
Laboratory staff qualifications and accuracy of proficiency test results.
Arch. Pathol. Lab. Med.
116:820-824[Medline].
|
| 22.
|
Matsunawa, T.
1986.
Poisson distribution, p. 20-25.
In
S. Kotz, and N. L. Johnson (ed.), Encyclopedia of statistical science, vol. 7. John Wiley & Sons, New York, N.Y.
|
| 23.
|
Merz, W. G., and G. D. Roberts.
1995.
Detection and recovery of fungi from clinical specimens, p. 709-722.
In
P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. ASM Press, Washington, D.C.
|
| 24.
|
Richardson, H.,
D. Wood,
J. Whitby,
R. Lannigan, and C. Fleming.
1996.
Quality improvement of diagnostic microbiology through a peer-group proficiency assessment program. A 20-year experience in Ontario. The Microbiology Committee.
Arch. Pathol. Lab. Med.
120:445-455[Medline].
|
| 25.
|
Salkin, I. F.,
R. J. Limberger, and D. Stasik.
1997.
Commentary on the objectives and efficacy of proficiency testing in microbiology.
J. Clin. Microbiol.
35:1921-1923[Medline].
|
| 26.
|
Sargent, J. D.,
L. Johnson, and S. Roda.
1996.
Disparities in clinical laboratory performance for blood lead analysis.
Arch. Pediatr. Adolesc. Med.
150:609-614[Abstract/Free Full Text].
|
| 27.
|
Schalla, W. O.,
S. O. Blumer,
R. N. Taylor,
H. W. Muir,
J. S. Hancock,
E. E. Gaunt,
S. K. Seilkop,
S. S. Huges,
D. A. Holzworth, and T. L. Hearn.
1995.
HIV blind performance evaluation: a method for assessing HIV-antibody testing performance, p. 409.
In
J. M. Krolak, A. O'Connor, and P. Thompson (ed.), Institute on critical issues in health laboratory practice: frontiers in laboratory practice research. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, Atlanta, Ga.
|
| 28.
|
Shahangian, S.
1998.
Proficiency testing in laboratory medicine.
Arch. Pathol. Lab. Med.
122:15-30[Medline].
|
| 29.
|
STSC, Inc.
1991.
APL*PLUS II system for Unix, version 4.
STSC, Inc., Rockville, Md.
|
| 30.
|
Stull, T. M.,
T. L. Hearn,
J. S. Hancock,
J. H. Handsfield, and C. L. Collins.
1998.
Variation in proficiency testing performance by testing site.
JAMA
279:463-467[Abstract/Free Full Text].
|
| 31.
|
Wilson, M. E.,
Y. C. Faur,
S. Schaefler,
I. Weitzman,
M. H. Weisburd, and M. Schaeffer.
1977.
Proficiency testing in clinical microbiology: the New York City program.
Mt. Sinai J. Med.
44:142-163[Medline].
|
| 32.
|
Woods, G. L., and J. A. Bryan.
1994.
Detection of Chlamydia trachomatis by direct fluorescent antibody staining. Results of the College of American Pathologists proficiency testing program, 1986-1992.
Arch. Pathol. Lab. Med.
118:483-488[Medline].
|
| 33.
|
Woods, G. L.,
T. A. Long, and F. G. Witebsky.
1996.
Mycobacterial testing in clinical laboratories that participate in the College of American Pathologists mycobacteriology surveys changes in practices based on responses to 1992, 1993, and 1995 questionnaires.
Arch. Pathol. Lab. Med.
120:429-435[Medline].
|
Journal of Clinical Microbiology, July 1999, p. 2297-2305, Vol. 37, No. 7
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Shahangian, S., Snyder, S. R.
(2009). Laboratory Medicine Quality Indicators: A Review of the Literature. Am J Clin Pathol
131: 418-431
[Abstract]
[Full Text]
-
Ramani, R., Chaturvedi, V.
(2003). Proficiency Testing Program for Clinical Laboratories Performing Antifungal Susceptibility Testing of Pathogenic Yeast Species. J. Clin. Microbiol.
41: 1143-1146
[Abstract]
[Full Text]
-
Xu, J, Millar, B C, Moore, J E, McClurg, R, Walker, M J, Evans, J, Hedderwick, S, McMullan, R
(2002). Comparison of API20C with molecular identification of Candida spp isolated from bloodstream infections. J. Clin. Pathol.
55: 774-777
[Abstract]
[Full Text]
-
Parsons, P. J., Reilly, A. A., Esernio-Jenssen, D., Werk, L. N., Mofenson, H. C., Stanton, N. V., Matte, T. D.
(2001). Evaluation of Blood Lead Proficiency Testing: Comparison of Open and Blind Paradigms. Clin. Chem.
47: 322-330
[Abstract]
[Full Text]
-
Rowen, J. L., Tate, J. M., Nordoff, N., Passarell, L., McGinnis, M. R.
(1999). Candida Isolates from Neonates: Frequency of Misidentification and Reduced Fluconazole Susceptibility. J. Clin. Microbiol.
37: 3735-3737
[Abstract]
[Full Text]